Marine Products and Age-Related Diseases: The Path from Pre-Clinical Research to Regulatory Approval for thpe Treatment of Neurodegenerative and Musculoskeletal Diseases

Marine-derived products are emerging for their potential in mitigating aging and age-related diseases. Among them, neurodegenerative and musculoskeletal diseases represent a major health challenge, often coexisting in older adults through interconnected biological axes. This narrative review evaluates the therapeutic potential of these chemically diverse products, integrating these two pathological domains through shared mechanisms and highlighting current experimental evidence from pre-clinical in vivo models to clinical translation toward regulatory approval. Pre-clinical evidence identified several candidates with neuroprotective, anti-sarcopenic, chondroprotective or anti-osteoporotic properties, and suggests modulation of key hallmarks of aging (e.g., mitochondrial dysfunction, proteostasis/autophagy, inflammation/senescence, and gut microbiota). A candidate pleiotropic efficacy across both disease domains was suggested for fucoidan, chitosan oligosaccharides, astaxanthin, fucoxanthin and ω-3 PUFAs. However, clinical translation remains highly limited: several marine products that, in animal models, engage disease-modifying mechanisms, fail to demonstrate disease modification in humans. Out of numerous explored products, only sodium oligomannate (GV-971) has achieved disease-specific regulatory approval for Alzheimer’s disease, but only in China, and still lacks a robust international consensus. Other compounds have either failed to replicate pre-clinical efficacy in human trials or have transitioned into commercial dietary supplements without approved therapeutic claims. Finally, translational bottlenecks hindering the clinical advancement of marine compounds were discussed. Future development should prioritize standardized formulations, mechanistic insight, aged animal models and multimorbidity-oriented trials to validate cross-domain tissue protection.

Authors

Institutions

Publication Details

Journal
Marine Drugs
Published
2026-11-12
DOI
https://doi.org/10.3390/md24110408
Primary Topic
Seaweed-derived Bioactive Compounds
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Marine Products and Age-Related Diseases: The Path from Pre-Clinical Research to Regulatory Approval for thpe Treatment of Neurodegenerative and Musculoskeletal Diseases

Marco Malavolta, Milena Fini, Giovanni Lai, Maria Elisa Giuliani et al.
Marine Drugs
Seaweed-derived Bioactive Compounds
article

Marine Products and Age-Related Diseases: The Path from Pre-Clinical Research to Regulatory Approval for thpe Treatment of Neurodegenerative and Musculoskeletal Diseases

Marco Malavolta, Milena Fini, Giovanni Lai, Maria Elisa Giuliani, Salvatore Vaiasicca, Francesca Veronesi, Serena Marcozzi, Giorgia Bigossi, Lúcia Martini, Davide Perini
article en

Abstract

Marine-derived products are emerging for their potential in mitigating aging and age-related diseases. Among them, neurodegenerative and musculoskeletal diseases represent a major health challenge, often coexisting in older adults through interconnected biological axes. This narrative review evaluates the therapeutic potential of these chemically diverse products, integrating these two pathological domains through shared mechanisms and highlighting current experimental evidence from pre-clinical in vivo models to clinical translation toward regulatory approval. Pre-clinical evidence identified several candidates with neuroprotective, anti-sarcopenic, chondroprotective or anti-osteoporotic properties, and suggests modulation of key hallmarks of aging (e.g., mitochondrial dysfunction, proteostasis/autophagy, inflammation/senescence, and gut microbiota). A candidate pleiotropic efficacy across both disease domains was suggested for fucoidan, chitosan oligosaccharides, astaxanthin, fucoxanthin and ω-3 PUFAs. However, clinical translation remains highly limited: several marine products that, in animal models, engage disease-modifying mechanisms, fail to demonstrate disease modification in humans. Out of numerous explored products, only sodium oligomannate (GV-971) has achieved disease-specific regulatory approval for Alzheimer’s disease, but only in China, and still lacks a robust international consensus. Other compounds have either failed to replicate pre-clinical efficacy in human trials or have transitioned into commercial dietary supplements without approved therapeutic claims. Finally, translational bottlenecks hindering the clinical advancement of marine compounds were discussed. Future development should prioritize standardized formulations, mechanistic insight, aged animal models and multimorbidity-oriented trials to validate cross-domain tissue protection.

Marine DrugsVol. 24(11)
Marche Polytechnic University (IT), Istituto Ortopedico Rizzoli (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Istituto Nazionale di Riposo e Cura per Anziani (IT)
Good health and well-being
Seaweed-derived Bioactive Compounds
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon